Is Metabolism of (R)-Ketamine Essential for the Antidepressant Effects?
The International Journal of Neuropsychopharmacology December 23, 2017 DOI: 10.1093/ijnp/pyx120 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Esketamine Ketamine |
| Citations | 17 |
| Key points | States that major depressive disorder affects approximately 10% to 20% of the US population and that, while SSRIs and SNRIs are widely used first-line treatments, roughly 30% of patients remain inadequately treated after a series of treatments and these medications take several weeks to show antidepressant effects. |
Abstract
Major depressive disorder (MDD) affects approximately 10% to 20% of the US population (Kessler et al. , 2005); thus, the economic burden of MDD is immense. Currently, selective serotonin reuptake inhibitors and serotonin- and noradrenaline-reuptake inhibitors are widely prescribed for patients with MDD as first-line treatments. However, these medications have several drawbacks; approximately 30% of patients remain inadequately treated even after a series of treatments and it takes several weeks for these medications to manifest their antidepressant actions (Rush et al. , 2006; Trivedi et al. , 2006).
Citations in the library
Cited by 11
- Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective Psychiatry and Clinical Neurosciences June 19, 2019
- Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochemical Pharmacology July 1, 2020
- Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers Therapeutic Advances in Psychopharmacology 2020
- Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites Translational Psychiatry November 7, 2019
- A historical review of antidepressant effects of ketamine and its enantiomers. Pharmacology, Biochemistry, and Behavior February 5, 2020
and 6 more in the library
Cites 10
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Archives of General Psychiatry August 1, 2006
- mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists Science August 19, 2010
- NMDAR inhibition-independent antidepressant actions of ketamine metabolites Nature April 24, 2016
- R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects Translational Psychiatry September 1, 2015
- Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study Biological Psychiatry November 4, 2015
and 5 more in the library